Clearstead Advisors’s Design Therapeutics DSGN Stock Holding History

Clearstead Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.2K	Buy	5,610 +5,000	+820%	+$62.3K	﹤0.01%	1355
2026 Q1	$6.49K	Hold	610	–	–	﹤0.01%	1692
2025 Q4	$5.72K	Hold	610	–	–	﹤0.01%	1997
2025 Q3	$4.59K	Hold	610	–	–	﹤0.01%	2186
2025 Q2	$2.06K	Hold	610	–	–	﹤0.01%	2315
2025 Q1	$2.35K	Hold	610	–	–	﹤0.01%	1877
2024 Q4	$3.76K	Hold	610	–	–	﹤0.01%	1766
2024 Q3	$3.28K	Hold	610	–	–	﹤0.01%	1774
2024 Q2	$2.04K	Hold	610	–	–	﹤0.01%	1814
2024 Q1	$2.78K	Hold	610	–	–	﹤0.01%	1269
2023 Q4	$1.62K	Sell	610 -610	-50%	-$1.4K	﹤0.01%	1320
2023 Q3	$2.88K	Buy	1,220 +610	+100%	+$2.85K	﹤0.01%	1348
2023 Q2	$3.84K	Hold	610	–	–	﹤0.01%	1074
2023 Q1	$3.52K	Buy	+610	New	+$4.56K	﹤0.01%	1060

Other funds holding DSGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Clearstead Advisors's DSGN Position: Q2 2026 in Review

Clearstead Advisors increased its Design Therapeutics (DSGN) stake by 820% in Q2 2026, buying an estimated $62.3K and bringing the position to 5,610 shares worth $81.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Clearstead Advisors first reported a position in DSGN in Q1 2023 and has held it in 14 quarters since. 40 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Clearstead Advisors held 5,610 shares of Design Therapeutics worth $81.2K as of Q2 2026.
Clearstead Advisors bought 5,000 Design Therapeutics shares in Q2 2026, an estimated $62.3K.
Design Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1355 holding.
Clearstead Advisors first reported a position in Design Therapeutics in Q1 2023 and has held it in 14 quarters since.
40 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.